Literature DB >> 20368187

A call for sharing: adapting pharmaceutical research to new realities.

Bernard H Munos1, William W Chin.   

Abstract

From the dawn of time, the sharing of knowledge has been one of the main forces driving science and innovation. Yet in recent decades, a proprietary culture, which wrongly posits that all intellectual property must be restricted, has spread across the pharmaceutical industry and threatens to stall the engine that has given us so many valuable treatments. This paper argues that pharmaceutical companies, together with universities and government agencies, stand to gain much from reversing that trend and engaging in widespread collaboration early in the research process to expand foundational knowledge and create a shared infrastructure to tap it.

Entities:  

Mesh:

Year:  2009        PMID: 20368187     DOI: 10.1126/scitranslmed.3000155

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  10 in total

Review 1.  Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.

Authors:  Evangeline Tzatzalos; Oscar J Abilez; Praveen Shukla; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2015-09-30       Impact factor: 15.470

2.  Realizing Our Potential in Biobanking: Disease Advocacy Organizations Enliven Translational Research.

Authors:  Kelly A Edwards; Sharon F Terry; Dana Gold; Elizabeth J Horn; Mary Schwartz; Molly Stuart; Suzanne D Vernon
Journal:  Biopreserv Biobank       Date:  2016-04-08       Impact factor: 2.300

Review 3.  Medications development to treat alcohol dependence: a vision for the next decade.

Authors:  Raye Z Litten; Mark Egli; Markus Heilig; Changhai Cui; Joanne B Fertig; Megan L Ryan; Daniel E Falk; Howard Moss; Robert Huebner; Antonio Noronha
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

4.  Learning from hackers: open-source clinical trials.

Authors:  Adam G Dunn; Richard O Day; Kenneth D Mandl; Enrico Coiera
Journal:  Sci Transl Med       Date:  2012-05-02       Impact factor: 17.956

Review 5.  Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Authors:  Elizabeth A Ottinger; Mark L Kao; Nuria Carrillo-Carrasco; Nicole Yanjanin; Roopa Kanakatti Shankar; Marjo Janssen; Marcus Brewster; Ilona Scott; Xin Xu; Jim Cradock; Pramod Terse; Seameen J Dehdashti; Juan Marugan; Wei Zheng; Lili Portilla; Alan Hubbs; William J Pavan; John Heiss; Charles H Vite; Steven U Walkley; Daniel S Ory; Steven A Silber; Forbes D Porter; Christopher P Austin; John C McKew
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

6.  Innovative partnerships for drug discovery against neglected diseases.

Authors:  Palle H Jakobsen; Ming-Wei Wang; Solomon Nwaka
Journal:  PLoS Negl Trop Dis       Date:  2011-09-27

7.  The Pharmaceutical Commons: Sharing and Exclusion in Global Health Drug Development.

Authors:  Javier Lezaun; Catherine M Montgomery
Journal:  Sci Technol Human Values       Date:  2015-01

Review 8.  Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients.

Authors:  Magdalini Papadaki
Journal:  Front Med (Lausanne)       Date:  2017-05-29

Review 9.  One Step Into the Future: New iPSC Tools to Advance Research in Parkinson's Disease and Neurological Disorders.

Authors:  Nguyen-Vi Mohamed; Frédérique Larroquette; Lenore K Beitel; Edward A Fon; Thomas M Durcan
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

10.  Are patents impeding medical care and innovation?

Authors:  E Richard Gold; Warren Kaplan; James Orbinski; Sarah Harland-Logan; Sevil N-Marandi
Journal:  PLoS Med       Date:  2010-01-05       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.